Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4514-z. [Epub ahead of print]
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A1,2, Okonji D3, Assersohn L4, Rigg A5, Sheri A6, Turner N3, Smith I3, Parton M3, Dowsett M7,8.
Breast cancer; Oncotype DX; RSPC, prognosis; Recurrence risk; Recurrence score